View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 18, 2017

CRT and Celgene sign drug discovery collaboration

Cancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a drug discovery collaboration with Celgene for the development and commercialisation of new anti-cancer treatments.

Cancer Research UK’s subsidiary Cancer Research Technology (CRT) has signed a drug discovery collaboration with Celgene for the development and commercialisation of new anti-cancer treatments.

The partnership represents an expansion of CRT’s translational model that now covers six industry partnerships.

It is centred on messenger ribonucleic acid (mRNA) translation, which is said to have the potential to produce treatments that can target specific characteristics of cancer cells.

CRT CEO Dr Iain Foulkes said: “This bold and exciting collaboration between one of industry’s leading innovators, Celgene, and CRT is part of our theme-based drug discovery approach and helps leverage our understanding of cancer biology and the needs of patients to drive the most promising discoveries into the clinic.

“CRT is set to lead research and development (R&D) activities to progress clinical candidates through Phase I trials.”

“This is our largest drug discovery collaboration to date and represents a major endorsement of the reputation and scale of our capacity and expertise in both drug discovery and clinical development by a leading industry partner.”

CRT is set to lead research and development (R&D) activities to progress clinical candidates through Phase I trials.

Under the terms of the five-year agreement, CRT will receive an upfront fee from Celgene, which will have the option to secure US rights to projects resulting from the collaboration.

Celgene will also have the option to secure global rights to completed projects, subject to the payment of additional option fees.

The company pursues drug discovery research in themed partnerships and delivers varied commercial partnering arrangements.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology